LivaNova   Report issue

For profit Phase 3
Founded: London United Kingdom (1987)
Status: No NME R&D (1987)

Organization Overview

First Clinical Trial
2008
NCT00736294
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrial Fibrillation (Phase 3)

Atrial Flutter (Phase 3)

Heart Failure (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 5